Residual pituitary enlargement in primary hypothyroidism despite 1 1/2 years of L-thyroxine therapy.
Pituitary hyperplasia consequent to untreated primary hypothyroidism undergoes impressive regression following thyroxine therapy. We describe a young man with primary hypothyroidism and pituitary hyperplasia, who showed significant but incomplete regression of pituitary enlargement despite 18 months of L-thyroxine therapy (1 year in replacement dose (150 micrograms/day) and an additional 6 months in suppressive dose (300 micrograms/day)).
Goswami
R
R
Department of Endocrinology, All India Institute of Medical Sciences, New Delhi, India.
Tandon
N
N
Sharma
R
R
Kochupillai
N
N
D000328:Adult; D006801:Humans; D006965:Hyperplasia; D007037:Hypothyroidism / Q000150:complications* / Q000188:drug therapy*; D008279:Magnetic Resonance Imaging; D008297:Male; D010902:Pituitary Gland / Q000473:pathology*; D013974:Thyroxine / Q000627:therapeutic use*
D013974:Thyroxine